As per the alliance agreement, Mnemosyne will own all IP generated and is responsible for clinical development and commercialization.
The collaboration is expected to focus on developing subunit selective NMDA receptor modulators (SNRMs) that Mnemosyne has identified.
The agreement will span for a period of two years and may be extended on mutual consent across other therapeutic programs as well.
The contract will use the capabilities of the companies across electrophysiology, medicinal chemistry, NMDA receptor pharmacology, computational chemistry and DMPK and in vivo pharmacology, Mnemosyne said.
Jubilant global drug discovery and development president and CEO Sri Mosur said this creative alliance further demonstrates Jubilant’s commitment to global R&D in enabling early discovery research towards optimal commercialization.